KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Operations (2016 - 2025)

Pfizer (PFE) has disclosed Cash from Operations for 17 consecutive years, with 5348000000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 20.43% to 5348000000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 11704000000.0, a 8.16% decrease, with the full-year FY2025 number at 11704000000.0, down 8.16% from a year prior.
  • Cash from Operations was 5348000000.0 for Q4 2025 at Pfizer, up from 4603000000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 26666000000.0 in Q4 2021 to a low of 1781000000.0 in Q2 2024.
  • A 5-year average of 6169277777.78 and a median of 4921500000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 566.21% in 2021, then tumbled 114.79% in 2023.
  • Pfizer's Cash from Operations stood at 26666000000.0 in 2021, then fell by 22.43% to 20685000000.0 in 2022, then tumbled by 74.67% to 5240000000.0 in 2023, then increased by 28.26% to 6721000000.0 in 2024, then fell by 20.43% to 5348000000.0 in 2025.
  • Per Business Quant, the three most recent readings for PFE's Cash from Operations are 5348000000.0 (Q4 2025), 4603000000.0 (Q3 2025), and 582000000.0 (Q2 2025).